Riyadh - Mubasher: Jamjoom Pharmaceuticals Factory Company (Jamjoom Pharma) registered an annual increase of 7.11% in net profits to SAR 168.21 million during the first quarter (Q1) of 2026, compared with SAR 157.03 million.
The earnings per share (EPS) climbed to SAR 2.40 in January-March 2026 from SAR 2.24 in the corresponding period a year earlier, according to the income statements.
Meanwhile, the revenues stood at SAR 481.38 million as of 31 March 2026, higher by 5.21% year-on-year (YoY) than SAR 457.53 million.
On a quarterly basis, the Q1-26 net profits leapt by 147.11% when compared with SAR 68.07 million in Q4-25, whereas the revenues hiked by 58.05% from SAR 304.57 million.
The CEO of Jamjoom Pharma, Tarek Hosni, commented: “Despite operating in a market that experienced an unexpected contraction and amid an environment of heightened geopolitical uncertainty, Jamjoom Pharma delivered a resilient and disciplined performance in Q1-26.”
“The continued ability to grow ahead of the market underscores the strength, scalability, and defensiveness of our business model, as well as the commitment and excellence of our teams across all markets,” the CEO added.
“Net profit grew faster than revenue, reflecting effective cost discipline, enhanced operating leverage, and a clear focus on value-accretive growth,” he continued.
Hosni emphasized: “This performance reinforces our ability to navigate volatility while remaining firmly aligned with our long‑term strategic priorities.”
"With a strong balance sheet and a clear roadmap for disciplined execution, Jamjoom Pharma remains well positioned to continue delivering calculated growth and long‑term value creation, even in a challenging external environment,” the CEO concluded.
During 2025, Jamjoom Pharma generated SAR 463.80 million in net profits, marking a 30.10% YoY surge from SAR 356.50 million.
